Abstract | PURPOSE: In two 6-month, double-blind, placebo-controlled studies, rotigotine transdermal system was well-tolerated and efficacious monotherapy in early-stage PD. This post hoc analysis of the long-term open-label extensions (NCT00594165; NCT00599196) of these studies assessed incidence and severity of dyskinesia in participants treated with rotigotine, with or without concomitant levodopa, for up to 6 years. METHODS: Open-label rotigotine was titrated to optimal dose (≤16 mg/24 h). Concomitant levodopa was permitted. Dyskinesia data, recorded using the Unified Parkinson's Disease Rating Scale Part IV, were pooled from the two open-label studies. RESULTS: Of 596 participants who received open-label rotigotine, 299 (50%) remained at trial closure; no patient discontinued due to dyskinesia. In the two studies, median exposure to rotigotine was 1910 days (∼5 years, 3 months), and 1564.5 days (∼4 years, 3 months). During up to 6 years of open-label rotigotine, 423/596 (71%) received levodopa. Dyskinesias were reported in 115/596 (19%) participants, 90/115 (78%) of who developed dyskinesia after levodopa was added; 25 reported dyskinesia in the absence of levodopa (includes patients who never received open-label levodopa, and those who reported dyskinesia before starting concomitant levodopa). Dyskinesia severity data were available for 107 of the 115 participants. In 56/107 (52%) participants, dyskinesia was considered 'not disabling' for all occurrences; the worst-case severity was 'mildly disabling' for 33/107 (31%), and 'moderately' or 'severely disabling' for 18/107 (17%; 3% of total participants). CONCLUSION: During treatment with rotigotine in patients with PD for up to 6 years the incidence of dyskinesia was low, and the dyskinesia was generally 'not disabling' or 'mildly disabling'.
|
Authors | Nir Giladi, Liesbet Ghys, Erwin Surmann, Babak Boroojerdi, Joseph Jankovic |
Journal | Parkinsonism & related disorders
(Parkinsonism Relat Disord)
Vol. 20
Issue 12
Pg. 1345-51
(Dec 2014)
ISSN: 1873-5126 [Electronic] England |
PMID | 25444083
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antiparkinson Agents
- Tetrahydronaphthalenes
- Thiophenes
- Levodopa
- rotigotine
|
Topics |
- Administration, Cutaneous
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Antiparkinson Agents
(administration & dosage)
- Disability Evaluation
- Dose-Response Relationship, Drug
- Double-Blind Method
- Dyskinesias
(diagnosis, epidemiology, etiology)
- Female
- Humans
- Kaplan-Meier Estimate
- Levodopa
(therapeutic use)
- Longitudinal Studies
- Male
- Middle Aged
- Parkinson Disease
(drug therapy)
- Sex Factors
- Tetrahydronaphthalenes
(administration & dosage)
- Thiophenes
(administration & dosage)
|